(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 August 2012 (02.08.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/101252 A2

(51) International Patent Classification:
C07K 16/40 (2006.01)

(21) International Application Number:
PCT/EP2012/051320

(22) International Filing Date:
27 January 2012 (27.01.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

11305088.4	28 January 2011 (28.01.2011)	EP
11305089.2	28 January 2011 (28.01.2011)	EP
11305513.1	29 April 2011 (29.04.2011)	EP
11305514.9	29 April 2011 (29.04.2011)	EP
11306039.6	12 August 2011 (12.08.2011)	EP
11306040.4	12 August 2011 (12.08.2011)	EP
11306201.2	22 September 2011 (22.09.2011)	EP
11306202.0	22 September 2011 (22.09.2011)	EP
11306449.7	8 November 2011 (08.11.2011)	EP
11306450.5	8 November 2011 (08.11.2011)	EP

(71) Applicant *(for all designated States except US)*: **SANOFI** [FR/FR]; 54, rue La Boétie, F-75008 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HANOTIN, Corinne** [FR/FR]; c/o SANOFI, Diabetes - R&D/Development, 54, rue La Boétie, F-75008 Paris (FR). **BESSAC, Laurence** [FR/FR]; c/o SANOFI, Diabetes - R&D/Development, 54, rue La Boétie, F-75008 Paris (FR). **CHAUDHARI, Umesh** [US/US]; c/o SANOFI US, R&D Bridgewater, Phase III - Clinical Development, Mail Stop: 55B-415B, 55 Corporate drive, New Jersey Bridgewater, 08807 (US).

(74) Agent: **SCHNEIDER, Rudolf**; c/o Sanofi-Aventis Deutschland GmbH, Patents Germany, Industriepark Höchst, Geb. K801, 65926 Frankfurt am Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2012/101252 A2

(54) Title: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS

(57) Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.